So this is odd. @RebeccaDRobbins article about "pay-to-play" clinical trials begins with the Chief Compliance Officer at Advarra expressing concerns about ethical issues raised by such studies. And yet Advarra is reportedly the IRB of record for a play-to-participate trial.
-
-
Yep. And then, as you of course know, there's IRB shopping, the use of IRB approvals as ethical and regulatory fig leaves, and the general absence of transparency related to how such IRBs operate, what studies they approve, and why they approve them.
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.